Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Guillermo Garcia-Manero, Manuel Ugidos, Maroof Hasan, Matthew Stokes, Matteo Della Porta, Amer Zeidan, Valeria Santini, Uwe Platzbecker, Rami Komrokji, Dimana Miteva, Veronika Pozharskaya, Anita Gandhi, Daniel Lopes de Menezes, Rajasekhar Suragani

Blood (2025) 146 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2025-5613

Published: 2025

Journal Articles

Luspatercept reduces cardiac stress and improves cardiac function in a TET2-deficient mouse model with features of heart failure with preserved ejection fraction: Evidence from phase 3 commands trial and pre-clinical studies

Manuel Ugidos, Sarita Nehra, Manoj Dokania, Gobinathan Rengarasu, Guillermo Garcia-Manero, Uwe Platzbecker, Anita Gandhi, Ching-Pin Chang, Ricardo Garcia, Jyoti Gulia, Rajasekhar Suragani, Maroof Hasan

Blood (2025) 146 (Supplement 1): 233.

https://doi.org/10.1182/blood-2025-233

Published: 2025

Journal Articles

Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)

Bijay Shankar Jaiswal, Manuel Ugidos, Hiroshi Kosugi, Kosei Matsue, Hiromi Murakami, Jin Hayakawa, Daniel Lopes de Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2024) 144 (Supplement 1): 6725.

https://doi.org/10.1182/blood-2024-201883

Published: 2024

Journal Articles

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Maroof Hasan, Shahid Tannu, Shikha Saini, Manuel Ugidos, Guillermo Garcia-Manero, Uwe Platzbecker, Ching-Pin Chang, Anita K. Gandhi, Ricardo Garcia, Rajasekhar N.V.S. Suragani

Blood (2024) 144 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2024-194241

Published: 2024

Journal Articles

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Sheida Hayati, Amer M. Zeidan, Guillermo Garcia-Manero, Uwe Platzbecker, Aarif Ahsan, Amit K. Verma, Srinivas Aluri, Manuel Ugidos Guerrero, Anita K. Gandhi, Rajasekhar N.V.S. Suragani, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2023-178674

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial

Manuel Ugidos Guerrero, Sujit Sheth, Olivier Hermine, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2023-179122

Published: 2023

Journal Articles

Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study

Rami S. Komrokji, Manuel Ugidos Guerrero, Guillermo Garcia-Manero, Amer M. Zeidan, Uwe Platzbecker, Sheida Hayati, Sadanand Vodala

Blood (2023) 142 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2023-178689

Published: 2023

Journal Articles

Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia

Aarif Ahsan, Wei Fang, Manuel Ugidos, Danny V Jeyaraju, Pierre Fenaux, Uwe Platzbecker, Olivier Hermine, John B. Porter, Rajasekhar N.V.S. Suragani, Sadanand Vodala, Anita K. Gandhi

Blood (2022) 140 (Supplement 1): 8188–8189.

https://doi.org/10.1182/blood-2022-166559

Published: 2022

Journal Articles

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi

Blood (2022) 140 (Supplement 1): 3865–3867.

https://doi.org/10.1182/blood-2022-166407

Published: 2022

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2021) 138 (Supplement 1): 804.

https://doi.org/10.1182/blood-2021-147465

Published: 2021

Journal Articles

Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) during Erythropoietic Response

Maciej W. Garbowski, Manuel Ugidos, Alberto Risueño, Rajasekhar N.V.S. Suragani, Jeevan K. Shetty, Sadanand Vodala, Anjan Thakurta, Martin Schwickart, John B. Porter

Blood (2021) 138 (Supplement 1): 761.

https://doi.org/10.1182/blood-2021-145975

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Luspatercept reduces cardiac stress and improves cardiac function in a TET2-deficient mouse model with features of heart failure with preserved ejection fraction: Evidence from phase 3 commands trial and pre-clinical studies

Impact of Mutational Landscape and Biomarkers on Response of Luspatercept (ACE-536) Treatment of Anemia in Non-Transfusion Dependent IPSS-R Lower Risk MDS Japanese Subjects (ACE-536-MDS-003- a Ph2 single-arm study)

Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with β-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial

Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study

Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia

Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) during Erythropoietic Response

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only